Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
It demonstrates a dose-dependent reduction in swelling in the rat carrageenan paw model
Jpn J Pharmacol
Ruboxistaurin maintains the bone mass of subchondral bone for blunting osteoarthritis progression by inhibition of osteoclastogenesis and bone resorption activity
PubMed Central PMCID: PMC4397928
is an oral active and potent CRTh2 receptor antagonist and potentially useful for asthma treatment
LY315920(Varespladib) endizoate It demonstrates a dose-dependent reductionVarespladib, aslo known as LY315920, is a secreted phospholipase A2 (sPLA2) inhibitor (IC50 = 50 750 nM for a range of sPLA2 isoforms). Varespladib reduces atherosclerosis and aneurysm formation in ApoE mice and in guinea pigs. Varespladib significantly reduces the post ACS inflammatory response in those with and without diabetes. Varespladib may be potentially useful for treatment of coronary artery disease. Product information CAS Number: 172732 68
US$ 12.00
US$ 700.00
US$ 17.49
US$ 60.95
US$ 91.00
US$ 425.00
US$ 25.00